{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T09:14:33Z","timestamp":1768295673753,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.drugalcdep.2017.11.017","type":"journal-article","created":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T13:12:09Z","timestamp":1514898729000},"page":"12-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial"],"prefix":"10.1016","volume":"184","author":[{"given":"Ryan T.","family":"Hurt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon O.","family":"Ebbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana T.","family":"Croghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell R.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard D.","family":"Hurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Taylor","family":"Hays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0005","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/S0140-6736(16)30272-0","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial","volume":"387","author":"Anthenelli","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0010","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/jpet.103.059758","article-title":"Interaction of the nicotinic cholinergic system with ethanol withdrawal","volume":"308","author":"Butt","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.amepre.2008.04.009","article-title":"A clinical practice guideline for treating tobacco use and dependence: 2008 update. A US Public Health Service report","volume":"35","author":"Clinical Practice Guideline Treating Tobacco Use, Dependence Update Panel Liaisons Staff","year":"2008","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0020","first-page":"CD006103","article-title":"Nicotine receptor partial agonists for smoking cessation","volume":"4","author":"Cahill","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0025","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1037\/a0038633","article-title":"Concurrent alcohol and tobacco treatment: effect on daily process measures of alcohol relapse risk","volume":"83","author":"Cooney","year":"2015","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0030","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cct.2012.02.014","article-title":"Tobacco dependence counseling in a randomized multisite clinical trial","volume":"33","author":"Croghan","year":"2012","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0376-8716(99)00130-1","article-title":"Drinking as a risk factor for sustained smoking","volume":"59","author":"Dawson","year":"2000","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jama.2013.283185","article-title":"Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers. A randomized trial","volume":"311","author":"Ebbert","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.108.147058","article-title":"The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system","volume":"329","author":"Ericson","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0050","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1177\/1060028014545806","article-title":"Varenicline in the treatment of alcohol use disorders","volume":"48","author":"Erwin","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0055","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00846549","article-title":"Measuring nicotine dependence: a review of the fagerstrom tolerance questionnaire","volume":"12","author":"Fagerstrom","year":"1989","journal-title":"J. Behav. Med."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0060","first-page":"162","article-title":"An epidemiologic analysis of co-occurring alcohol and tobacco use and disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"29","author":"Falk","year":"2006","journal-title":"Alcohol Res. Health"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0065","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00213-010-2160-9","article-title":"A preliminary investigation of varenicline for heavy drinking smokers","volume":"215","author":"Fucito","year":"2011","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0070","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1200\/JCO.2009.26.3343","article-title":"Randomized phase II trials: inevitable or inadvisable?","volume":"28","author":"Gan","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.296.1.47","article-title":"Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial","volume":"296","author":"Gonzales","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0080","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/ntr\/ntp077","article-title":"A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics","volume":"11","author":"Hays","year":"2009","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0085","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jsat.2010.08.009","article-title":"Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: an open-label pilot study","volume":"40","author":"Hays","year":"2011","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0090","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","article-title":"The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire","volume":"86","author":"Heatherton","year":"1991","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0095","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.drugalcdep.2005.08.018","article-title":"Do smokers with alcohol problems have more difficulty quitting?","volume":"82","author":"Hughes","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/1462220031000070552","article-title":"Measures of abstinence in clinical trials: issues and recommendations","volume":"5","author":"Hughes","year":"2003","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14622200701188919","article-title":"Effects of abstinence from tobacco: valid symptoms and time course","volume":"9","author":"Hughes","year":"2007","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0110","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1360-0443.1995.tb02816.x","article-title":"Nicotine patch therapy for smoking cessation in recovering alcoholics","volume":"90","author":"Hurt","year":"1995","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0115","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.1996.03530380039029","article-title":"Mortality following inpatient addictions treatment: role of tobacco use in a community-based cohort","volume":"275","author":"Hurt","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial","volume":"296","author":"Jorenby","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0125","doi-asserted-by":"crossref","first-page":"681","DOI":"10.15288\/jsa.2004.65.681","article-title":"A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment","volume":"65","author":"Joseph","year":"2004","journal-title":"J. Stud. Alcohol"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0130","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ADM.0b013e31829623f4","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence","volume":"7","author":"Litten","year":"2013","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.biopsych.2009.01.029","article-title":"Varenicline reduces alcohol self-administration in heavy-drinking smokers","volume":"66","author":"McKee","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/JCP.0b013e3182870551","article-title":"Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial","volume":"33","author":"Meszaros","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00213-012-2717-x","article-title":"Varenicline decreases alcohol consumption in heavy-drinking smokers","volume":"223","author":"Mitchell","year":"2012","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0150","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1521-0391.2013.12037.x","article-title":"Varenicline and neuronal nicotinic acetylcholine receptors: a new approach to the treatment of co-occurring alcohol and nicotine addiction?","volume":"22","author":"Nocente","year":"2013","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0155","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1097\/01.ALC.0000102700.72447.0F","article-title":"Alpha 4 beta 2 nicotinic acetylcholine receptors modulate the effects of ethanol and nicotine on the acoustic startle response","volume":"27","author":"Owens","year":"2003","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0160","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.drugalcdep.2013.06.019","article-title":"Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence","volume":"133","author":"Plebani","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0165","series-title":"Suicidality Issues in Clinical Trials: Columbia Suicide Adverse Event Identification in FDA Safety Analyses 2007 [Internet]","author":"Posner","year":"2007"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0170","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/014662167700100306","article-title":"The CES-D scale: a self-report depression scale for research in the general population","volume":"1","author":"Radloff","year":"1977","journal-title":"Appl. Psychol. Meas."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0175","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00213-015-3878-1","article-title":"The role of varenicline on alcohol-primed self-administration and seeking behavior in rats","volume":"232","author":"Randall","year":"2015","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0180","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejca.2008.10.029","article-title":"Optimising the design of phase II oncology trials: the importance of randomisation","volume":"45","author":"Ratain","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0185","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomized phase II trials and a proposal for phase II screening trials","volume":"23","author":"Rubinstein","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0190","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0195","series-title":"Measuring Alcohol Consumption: Psychosocial and Biochemical Methods","first-page":"41","article-title":"Timeline follow-back: a technique for assessing self-reported alcohol consumption","author":"Sobell","year":"1992"},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0200","doi-asserted-by":"crossref","first-page":"12518","DOI":"10.1073\/pnas.0705368104","article-title":"Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking","volume":"104","author":"Steensland","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0205","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA) [Internet] [cited 2017 May 11]. Results from the 2015 national survey on drug use and health: detailed tables. Available from: https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUH-DetTabs2015\/NSDUH-DetTabs-2015\/NSDUH-DetTabs-2015.htm#tab2-46b."},{"key":"10.1016\/j.drugalcdep.2017.11.017_bib0210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0741-8329(01)00135-5","article-title":"Potential regulation of nicotine and ethanol actions by alpha4-containing nicotinic receptors","volume":"24","author":"Tritto","year":"2001","journal-title":"Alcohol"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617306075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617306075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:53:32Z","timestamp":1759827212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871617306075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":42,"alternative-id":["S0376871617306075"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.11.017","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}